Yüklüyor......
Scientific Rationale for Combined Immunotherapy with PD-1/PD-L1 Antibodies and VEGF Inhibitors in Advanced Hepatocellular Carcinoma
A successful phase III trial for the combination of atezolizumab and bevacizumab (the IMbrave150 trial) in advanced hepatocellular carcinoma has recently been reported. This is groundbreaking because nivolumab and pembrolizumab, both programmed cell death-1 (PD-1) antibodies, have failed to show eff...
Kaydedildi:
| Yayımlandı: | Cancers (Basel) |
|---|---|
| Yazar: | |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
MDPI
2020
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC7281246/ https://ncbi.nlm.nih.gov/pubmed/32349374 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.3390/cancers12051089 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|